Piper Jaffray Reiterates Underweight on Teva Pharma (TEVA) Following FDA Approval of Ajovy
Tweet Send to a Friend
Piper Jaffray analyst, David Amsellem, reiterated an Underweight rating and $13.00 price target on Teva Pharma (NYSE: TEVA) following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
